New FDA breakthrough-drug category--implications for patients

Comment

Jonathan J Darrow et al. N Engl J Med. 2014.

. 2014 Jul 3;371(1):89-90.

doi: 10.1056/NEJMc1405337.

No abstract available

Comment on

New FDA breakthrough-drug category--implications for patients.
Darrow JJ, Avorn J, Kesselheim AS. Darrow JJ, et al. N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493. N Engl J Med. 2014. PMID: 24670173 No abstract available.
New FDA breakthrough-drug category--implications for patients.
McClellan M, Sigal E. McClellan M, et al. N Engl J Med. 2014 Jul 3;371(1):87-8. doi: 10.1056/NEJMc1405337. N Engl J Med. 2014. PMID: 24988577 No abstract available.
New FDA breakthrough-drug category--implications for patients.
Murray BE. Murray BE. N Engl J Med. 2014 Jul 3;371(1):88. doi: 10.1056/NEJMc1405337. N Engl J Med. 2014. PMID: 24988578 No abstract available.
New FDA breakthrough-drug category--implications for patients.
Velleca M. Velleca M. N Engl J Med. 2014 Jul 3;371(1):88-9. doi: 10.1056/NEJMc1405337. N Engl J Med. 2014. PMID: 24988579 No abstract available.
New FDA breakthrough-drug category--implications for patients.
Ricart AD. Ricart AD. N Engl J Med. 2014 Jul 3;371(1):89. doi: 10.1056/NEJMc1405337. N Engl J Med. 2014. PMID: 24988580 No abstract available.